In May BioClinica was poised to buy etrials but its bid collapsed and in June Merge Healthcare made the acquisition. Since then BioClinica has moved quickly to expand its business, buying CardioNow at the start of September and now acquiring Tourtellotte.
The purchase of US-based Tourtellotte expands BioClinica’s eClinical offering by adding tcVisualise, supply chain simulation software, and interactive voice and web response technology (IXR).
By making these additions BioClinica believes it can “improve the overall clinical trial process” of its clients by adding products that can increase efficiencies. One of these products is tcVisualise which helps study managers “develop the perfect clinical supply plan”.
The software is used by four of the top 10 global pharma companies, according to BioClinica, which use it to reduce product waste, trial delays and lost patient enrollment due to product stockouts.
In addition BioClinica adds Trident to its portfolio by acquiring Tourtellotte. Trident is an IXR that can help clients remotely manage all aspects of trials including patient screening, enrollment, randomisation and distribution.
BioClinica believes this is the next-generation of IXR and that it redefines how the technology can be used by the biotech industry. The system has been built specifically for the web and consequently is free from the issues that are present in retrofitted software.
The acquisition of Tourtellotte by BioClinica follows on from its takeover of CardioNow. BioClinica acquired CardioNow from Agfa HealthCare to improve its ability to share, track and archive medical images from multi-centre clinical trials.
Following the acquisition BioClinica has begun integrating CardioNow’s technology into its electronic data capture (EDC) system, a process that the company said would take up to 45 days from September 1.
Once this process is complete BioClinica said it will offer clients immediate cost savings on each of the 200 clinical trials it is currently supporting.